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Advances in biomedical science are leading to upsurge synthesis of nanodelivery systems for drug delivery. The
systems were characterized by controlled, targeted and sustained drug delivery ability. Humans are the target of
these systems, hence, animals whose systems resembles humans were used to predict outcome.
Thus, increasing costs in money and time, plus ethical concerns over animal usage. However, with consideration
and planning in experimental conditions, in vitro pharmacological studies of the nanodelivery can mimic the in vivo
system. This can function as a simple method to investigate the effect of such materials without endangering
animals especially at screening phase.
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Nanodelivery system (NDS) is a branch of Nanomedicine
characterized by controlled, targeted and sustained drug
delivery ability, a limitation and drawback that is currently
limiting conventional drug delivery system especially
in drug delivery to tight areas like the brain [1]. NDS,
due to their small sizes usually below 100 nm and
unique physico-chemical and biological properties, are
now becoming the favourable system in drug delivery
and imaging system covering wider ailments including
cancers and central nervous pathologies [2,3]. Drugs
susceptible to enzymatic degradation and/or pH destabi-
lization can be incorporated into this delivery system, it
also offer them with additional possibilities of targeted
and controlled release potential [4]. However to achieve
these foreseeable advantages offered by nanodelivery
systems, challenges which include developing toxic-free
system, improved biocompatibility, effective drug loading,
proper targeting, transport and release ability must be
ascertained [1]. Biocompatibility and bio-distribution are
part of the key to success for drug development in achiev-
ing its aim, consequently more in vitro and in vivo study
needed to achieve the desired characteristics.* Correspondence: sharida@upm.edu.my
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unless otherwise stated.However, with changes and improvement in drug de-
livery via NDS comes a price (possible toxic effect), the
evaluation of which is important before any biological
application can be introduce. In 2004, the term nanotoxi-
city was coined; referring to the study of the potential
toxic impacts of nanoparticles on biological and ecological
systems [5]. The field arose due to concern over the
growing field of nanotechnology and the potential health
effects of nano-materials, especially to humans. The low
soluble or insoluble type nano-material capable of passing
through various defence systems because of their tiny
size are of the greatest concern [6]. The toxicity and bio-
distribution of these delivery systems could be influenced
by the synthetic process; coating materials; particle sizes
and or route of administration [7,8]. Hence, toxicity and
distribution studies should target these to evaluate the
potential of NDS in drug delivery.
Animals have been in the forefront of chemical toxicity
test, including drugs intended for human consumption
[9]. In 2005, 20% of the over 10 billion euro spent on
animal experiments worldwide and 100million animals
used were in toxicity studies [9]. Although, animal
usage is a part of the legislation before chemical usage
is allowed for both life and environmental protections
[10]. The values of the obtained results are sometimes
challenged with respect to transfer to humans, extreme
doses application during the studies and a time a false
positive correlation are made with respect to the lowLtd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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based-studies are generally costly in term of money and
time, plus ethical issues associated with it, these reasons
make tissue and cell-based exposure studies very useful
for toxicity screening of new compounds (nanoparticles
inclusive). Therefore, human as well as other animal tissue/
cells will continue to serve as an alternative (in-vitro) test
methods. The application of which may provide endpoints
result, which are directly associated with specific organs.
Nevertheless, it is well acknowledged, especially in the
European community that cell and tissue cultures will not
be able to replace animal tests completely [11]. This is
mainly due to the complexity of the human and the short
lifetime of culture, negating for the assessment of chronic
toxicity needed before human application [11].
In the past, cytotoxicity study used few survival mech-
anisms following exposure to the chosen chemicals,
mechanism like mitochondrial activity, membrane dam-
age and enzymes leakages into the culture media were
studied. However, advances were made over the years,
which resulted in cell usage for gene analysis in toxicity,
microscopic changes in cell cytoskeleton due to toxicity
among others [12-15]. This review aimed at reviewing
some of those methods used in assessing nanomaterial
toxicity using cell/tissue culture technique, with emphasis
on their advantage over entire animal usage, especially
during screening processes.
Review
Nanodelivery systems effects in relationship to dose
and time
Among the barrage of methods used in the NDS toxicity
assessment is the whole cell quantification following
exposure to certain concentration of the expected toxic
nanomaterial as compared to the untreated cell [2,3]. These
methods have the advantage of conveying the actual
number of viable cells, an increase (cell proliferation) or
decrease (cytotoxicity) in comparison to control (untreated
cells). In some instances, they measure the activity of viable
cells in the treated sample and the control, indirectly
counting live and dead cells [2,3].
Trypan blue is an example of quantitative dye exclusion
assay. In this experiment, cells are treated with NDS or
any chemical/drug for a desired period, then stained with
trypan blue to observe for cell proliferation or cell’s dead
[16]. The dye is called an exclusion diazo dye, which is
taken up by dead cells only, but excluded, by viable cells
[16]. The cells are viewed at higher magnification using a
light microscope, where unstained cells reflect the total
number of viable cells recovered from a given treatment.
The toxicity potential of zinc-layered hydroxide (ZLH)
and its corresponding cetirizine nanocomposite (CETN)
were tested on normal Chang liver cells after 24 hours of
treatment using the trypan blue stain; it was done to showdose-dependent toxic effects of the nano-carrier (ZLH) as
compared to the corresponding intercalated counterpart
(CETN) [17]. Other nanomaterial tested using this
method included but not limited to zinc oxide (ZnO),
copper oxide (CuO) and multi wall carbon nanotubes
(MWCNT) [12].
Stress exposure in the form nutrient deprivation or
drugs induced toxicity, could lead to necrotic or apoptotic
death at the cellular level [18]. Propidium iodide and
acridine (AOPI) are examples of double dye stain; they
can be used to study the apoptotic and necrotic cell
death. Viable cells stain green, while apoptotic cells stain
green and shrunken with condensation of the nucleus,
the necrotic cells stain red [18]. These morphological
changes will appear under fluorescence microscope
with AOPI stain. Propidium iodide (PI) intercalates into
double-stranded nucleic acids of dying or dead cells as
it can penetrate damaged cell membranes. It is excluded
by viable cells, but acridine orange (AO) can penetrate
intact membrane to stain viable cells [18]. Copper oxide
nanoparticles were shown to induce apoptosis and subse-
quent cell death, in human skin keratinocytes, utilizing
the AOPI staining technique [13]. Apoptosis is generally
regarded as an active or programmed form of cell death. It
is the preferred cell death; it allows the normal immune
system to get rid of the demise cells and tissues from the
system [14]. In contrast to this method of cell death is
the necrotic method, also referred to as uncontrolled or
pathological cell death. The two systems, are not exclu-
sively separated as they may happen at the same time on
the same tissue, especially where different concentrations
were used [14].
As stated earlier apoptotic cells stands the chances
of being engulfed by neighbouring immune cells, but
necrosis may lead to a secondary effect especially where
immunity has weakened and or inefficient. These and
other double dye studies are capable of screening NDS
and other compounds at the cellular level for a possible
cell death method before endangering animal or human
lives. Using this technique, silver nanoparticle was shown
to have both apoptotic and necrotic effects on breast
cancer cells (MCF-7) in a dose dependent fashion [19].
Doses below 50 μg/mL demonstrated apoptotic death
and above 80 μg/mL caused more of necrotic cell death.
Not just killing the cancer cell is important, but also
what happen after cancer cell death. The proceeding
secondary reaction due to the toxic substances release
to the surrounding normal cells by the dying cancer cells
could be more deadly than cancer itself [20]. A clinical
syndrome called tumour lysis syndrome seen in the case
cancer cells lysis, could be reduce if apoptosis is induce
more in cancer treatment rather than necrosis. Thus,
results like this one could be handy in deciding doses
to be use during animal and subsequent clinical trials.
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Cellular metabolism and cell membrane integrity as func-
tions of living cells were used in the past to assess drug
and other chemical’s toxicity. Now they are in use for
NDS screening [21]. Proliferation assay like MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
and neutral assay are typical examples of functional
assessment used in toxicity and or efficacy studies.
They are rapid and convenient in determining viable
cell number in proliferation or cytotoxicity studies. While
lactate dehydrogenase (LDH) assay is, an example of cell
membrane integrity study commonly applied in the
study of nanoparticle toxicity, as well as other drugs
and chemicals intended for human or environmental
uses [21]. LDH is a cellular enzyme that is release into
the cytoplasm upon cell lysis. The assay, therefore, can
be used to measure membrane integrity. Principally the
assay work by converting lactate to pyruvate through
oxidation by the LDH, subsequently Pyruvate reacts with
the tetrazolium salt to form formazan, water-soluble forma-
zan dye that can be detected by a spectrophotometer [21].
In the case of MTT, the assay is dependent on the
reduction of tetrazolium salt MTT (3-(4,5-dimethylthazol-
2-yl)-2,5-diphenyl tetrazolium bromide) by mitochondrial
dehydrogenase of only viable cells to form a blue for-
mazan product [15]. Neutral red on the other hand is
an uptake viability assay [22]. Principally it works by
the accumulation of the dye in the lysosomes of unin-
jured cells.
Utilizing some of the above-described assays, doses and
time-dependent effect of different types of nanomaterial
was evaluated to stimulate and estimate possible in vivo
effect [12,13,17]. In most instances, 24-72h period was
employed to determine these effects, which will have been
days to weeks if similar effects were to be determined
in animals. For example, eighty experimental animals of
both sexes were used to study the possible toxicity of a
synthesized titanium oxide nanoparticle of different
sizes and over three weeks period used [23]. The tissues
collected from these animals undergoes several days of
processing before a decision emerged as to either the ti-
tanium oxide nanoparticle used where toxic or not [23].
Above stated assays will have been a better choice in
screening these nanoparticles for their likely toxicity, and
where toxicity exists, modification can be made at the
level of synthesis with the view to address what causes the
toxicity. Satisfactory results obtained from these in vitro
assays will help in designing a successful in vivo study,
limiting wastage in lives, money and time.
Oxidative stress studies of nanodelivery systems
In vitro assays such as nitric oxide (NO) assay (Greiss
reaction) are used as a measure of free radical produc-
tion following exposure to NDS or any oxidative stressinducing drugs [24]. This measurement provides a sur-
rogate marker and quantitative indicator of nitric oxide
production due to a nano-delivery treatment of particular
cell line or tissue. Other oxidative stress assays such as
glutathione reductase (GR), reactive oxygen species (ROS)
are also valuable in assessing oxidative stress potential
of nano-delivery systems. Cytotoxicity and free radical
assessment via nitric oxide analysis is becoming very
curial [25]. This is so due to the growing evidence, that
high concentrations of nitric oxide (NO) in the brain
might be involve in a variety of neurodegenerative dis-
eases, of which Parkinson disease is one of them. Others
are Alzheimer's, cerebral ischemia and epilepsy [25].
These and other related oxidative stress markers associ-
ated with different diseases, including cancers could be
predicted with ease using cell culture techniques [26]. The
timing of which could be considered relatively short when
compared to animal studies of similar aim. Within 24h of
exposure, titanium oxide nanoparticle demonstrated a
dose related increase in reactive oxygen species from nor-
mal human bronchial epithelium (BEAS-2B) [27]. In the
same study, a relationship was established between pro-
duction of ROS and glutathione reductive enzymes (GSH)
depletion. Recently, an important development was dem-
onstrated in the treatment of cardiomyopathy with cerium
oxide (CeO2) nanoparticles [28]. This group of nanoparti-
cles were shown to modulate oxidative stress in trans-
genic mice with cardiomyopathy through free radical
scavenging activity. The promising result was generated
from animal model study, but the pre-requisite and pre-
liminary findings were obtained from cell culture models
(29. 30). Where, CeO2 nanoparticles was shown to res-
cued HT22 cells from oxidative stress-induced cell death
[29], in another related study it was demonstrated to pro-
tect normal human breast cells from radiation-induced
apoptotic cell death [30]. Here, in vitro studies predicted
an outstanding animal result, negating the need for exces-
sive animal usage. Thus, proper screening and designing
of preliminary cell culture work will likely limit the num-
ber of animal to be use, indirectly cutting down cost and
preserving ecological balance.
Uptake mechanism and blood brain barrier delivery
of drugs
The cellular uptake and delivery of nanoparticles across
the blood brain barrier is another aspect of pharmacology
where cell culture technology is of essence. With proper
usage of available in vitro techniques, tedious procedure
like micro dialysis, used in evaluating delivery of nanopar-
ticles and other drugs to the brain can be minimize. Other
molecular details like the receptor involve in nanoparticle
transport across the BBB could also be explore using
these models [31]. A group of scientist demonstrated the
role of temperature and alternative receptor in transporting
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cylcyanoacrylate nanoparticle (PEG-PHDCA) to the brain
[31,32]. These researchers used a relatively simple and
cheap in vitro BBB model [31,32]. These cell culture models
are becoming important tools in investigating drug delivery
to the brain without necessarily torturing animals, espe-
cially during the initial screening phase [33,34]. Unlike the
animal models, cell culture technology has the advantage of
rapid evaluation in nanoparticle uptake mechanism, toxicity
potentials and other related molecular mechanism needed
in achieving drug delivery to the CNS.
The uptake and internalization of drugs intercalated
into NDS can be studied with relative ease using in vitro
cell models. An optical microscope and electron spin
resonance (ESR) spectroscopic studies exemplifies this
[15]. Where, the mechanism of uptake and internalization
of iron oxide nanoparticles (IONs) into a brain tumour
cell were shown [15]. A water dispersible iron oxide
nanoparticle based formulation that was loaded with an
anticancer agent also showed good cell penetration via an
in vitro modelling [35]. The NDS (IONs) get internalize
into the cell through cell membrane invagination, forming
an early endosome that transformed into a late endosome
within five minutes, then later a lysosome containing
the particle and drug [18,36,37]. Entrance and uptake
of paclitaxel-LDH nanoparticles bounded with FITC
into cervical cancer was also studied using fluorescence
and transmission electron microscope (TEM). The two
demonstrated endocytosis as a means of cell entrance
by the nanoparticles [9]. Demonstrating these, effects in
animals require many lives to be sacrifice at intervals,
added to which is a long and a lacklustre process needed
before the result is acquired in most cases [38].
In the near future, thousands of these drug delivery
vehicles may be synthesized for the treatment and diag-
nosis of CNS disease. Consequently, a BBB in-vitro cell
culture models that closely resembles the in-vivo system,
reflecting at least the characteristics “barrier”, are in high
demand. This is to minimise cost and other ethical issues
attributed with in-vivo test systems. The In vitro BBB
models are usually made-up of cerebral capillary endothe-
lial or choroid plexus epithelial cells mostly of porcine
in origin that closely resembles the animal brain system
[33]. Interestingly, a reasonable correlation between, these
in vitro models and the animal models existed [39]. Thus,
strengthen further the importance of alternative to animal
in BBB drug delivery studies.
Live cells imaging in nanoparticle studies
Live cell imaging studies are other emerging in vitro
techniques used in the study of nanoparticles and other
related drugs [34]. With the live cell imaging systems,
cellular activity like mode of death, proliferation and in-
hibition as a result nanoparticle or other compoundsexposure can be studied. This method observe living
cells; images are acquired from microscopes and other
high content screening systems. The system gives a better
view of cellular dynamics as it relates to any form of
treatment and the researcher sees changes, as they are
unfolding.
Cancer diagnosis and its therapy are among the areas
that benefited from nanoparticles and live cell imaging
systems studies [40]. Huge advances emerged through
studying the dynamic biological processes taking place
during cancer treatment [41,42]. This technique enabled
researchers to follow the movement of individually labelled
nanoparticles to specific parts of the cell. In some instances
they are able to look at the receptor mediated transport
and entrance of the particles into the chosen cells [34,40].
Two different types of nanoparticles (polystyrene and silica
nanoparticles) were quantitatively analysed and localised in
the cytoplasm and nucleus of Hep-2 cells about one hour
after treatment using the live cell imaging [40]. Quantifica-
tion was done through the fluorescence intensities of the
tagged nanoparticles in the cytoplasm and nucleus of the
cells. This observation has added to the list of nanoparticles
with the capability of gene transfer into the nucleus.
Nanoparticles in cancer screening
Over the last six decades or so more than 85,000 com-
pounds were screened against cancers, most of which
using short-term assays [43]. Cell and tissue culture
(in vitro) studies were used as a baseline test in screening
these compounds for their anti-cancer activity [43].
Significant number of the compounds were initially
considered effective and promising, but failed clinical test
in treating cancer [43]. By far the number of compounds
that failed outweighs those that succeed to clinical usage
[43]. The lost in time, money and more importantly lives,
would likely wither if proper screening of intending anti-
cancer agent were maximally utilized. One way of screen-
ing nanoparticles for possible anti-cancer activity is
through in vitro methods using cells or tissues.
Cancer nanotechnology is emerging as result of inter-
disciplinary research and has great potential application
in diagnosis and treating cancers [44]. As such, synthesis
of hundreds of nano-biotechnology base cancer treatment/
diagnostic tools is on the increase, this is to cater for
cancer, a major public health problem [44,45]. Targeted
drug deliveries in cancer treatment with reduce toxicity
to surrounding normal cells and increase efficiency is but
a few advantages explored while using this nanodelivery
system [45]. Crossing the blood brain barrier to diagnose
and treat CNS tumours, control release and increase
solubility are also additional advantages of NDS [45].
Achieving these involves synthesizing and re-synthesizing
several nanodelivery systems using nanotechnology, each
time adjusting for a particular parameter to achieve the
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for testing a peculiar property, doing this on animal’s
means a lot in terms of time and money.
Nanoparticle in cancer treatment was studied using an
in vitro model, where uptake of the polylactic-co-glycolic
acid (PLGA) nanoparticles coated with polyvinyl alcohol
(PVA) was shown to be 1.4 times less than that coated
with vitamin E TPGS on a colorectal cancer cell line [45].
Recently our team demonstrated the effect of coating on
iron oxide nanoparticle intercalated with Gallic acid in a
cell culture-base study [46]. The magnetic nanoparticles
with average size of 11.4 nm and coated with Polyethylene
glycol (PEG) showed enhanced anti-cancer effect on
breast cancer but not lung cancer compared to pure
Gallic acid [46]. However, the same nanodelivery system
containing Gallic acid coated with chitosan demonstrated
lesser anti-cancer activity on both breast and colon cancer
compare to the pristine Gallic acid [3]. Thus, cell culture
studies allowed for the choice of better polymer on this
nanoparticle containing Gallic acid in cancer treatment. It
also helps in the screening of different cancer for which
the delivery system will likely have better effect on.
The size-dependent quantum effect of nanoparticle is
providing them unique physico-chemical and biological
properties that makes them fundamentally different from
their corresponding bulk counterpart, especially in cancer
diagnosis and treatment [47]. In vitro cell proliferation
assays were selected to show time and dose dependent the
cytotoxicity of zinc oxide nanoparticles on colon cancer
cells [47]. The same technique demonstrated the effect
of particles sizes on the chosen cancer cells, where sizes
below 30 nm showed higher toxicity compared to 90 nm
size particles. The above-mentioned experiments look,
sound relatively simple and cheap. However, the infor-
mation generated could serve as a reasonable baseline
in predicting possible in vivo outcome.
Limitation of cell culture technique
Absence of immune effect, blood proteins, the endocrine
system and the general lack of complex interaction of
the whole animal in most in vitro system is limiting the
potential transfer of some cell culture-based results of
nanoparticle studies to animals/humans [48]. Tissue-
specific differentiation functions of many cells and their
physiological context of the primary cell cultures in in vitro
systems are lost, like the loss of bio-transformational
enzymes in primary liver cell cultures [49]. This lost in
bio-transformational enzymes of liver cells will hinder
the usage of primary liver cells in assessing nanoparticle
for metabolism and toxicity potentials.
The assumption of neurotoxic potential of a compound
if tested on neuronal cell line without considering the
effect of blood brain barrier in animal model may lead to
erroneous conclusion [48]. Recently, a group of researcherstried to evaluate the toxicity potential of zinc oxide nano-
particle on both cell and animal based models [50]. The
two models showed a dose-dependent toxicity potential
by the nanoparticle. However, in animal-based study,
additional information emerged that relate route of
administration and toxicity by the same delivery system.
Another disturbing conclusion made from in vitro studies
are that of glass fibre’s ability in generating reactive oxygen
species and causing oxidant stress leading to DNA
damage, but a low pathogenic potential was reported
when tested in animal models [51]. In vitro study also
reported kaolin to be as cytotoxic as quartz, and purified
single-walled carbon nanotubes not inducing oxidative
stress in cell studies but resulted in progressive interstitial
fibrosis in mice [51]. In general, animal systems are
extremely complicated, and the closer a proposed nano-
particle is for human use, the more it requires animal
model research. However, properly planned in vitro
technique will likely serve as a good screening mechanism
for NDS. This will likely reduce cost, time and more
importantly preserve more lives of animal in the future.
Conclusion
There are many variables to consider when working with
nanomaterial and these include type of material, their size,
shape, surface, charge, coating, dispersion, agglomeration,
aggregation, concentration and matrix. By carefully con-
sidering the experimental conditions, in vitro toxicity,
bio-distribution, BBB deliveries, mechanism of cellular
uptake and other related studies of nanoparticles can
minimise the usage of in vivo system to assess these.
This can play a role as a simple method to investigate
the effect of such materials. However, animal systems
are extremely complicated with unique bio-distribution,
clearance, immune response, and metabolism. Therefore,
in vitro study can only complement animal studies in asses-
sing NDS. However, adequate and meaningful screening
using cell culture technique will ensure reduction in the
number of animal usage significantly.
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